Previous close | 68.53 |
Open | 68.25 |
Bid | 68.36 x 800 |
Ask | 68.39 x 800 |
Day's range | 68.16 - 68.79 |
52-week range | 60.47 - 76.56 |
Volume | |
Avg. volume | 6,318,930 |
Market cap | 211.946B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 35.79 |
EPS (TTM) | 1.91 |
Earnings date | N/A |
Forward dividend & yield | 1.45 (2.12%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | 81.81 |
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes? Let's find out.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.